| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8 | NLRP3 + CD47 combo is novel; both targets actively pursued |
| Mechanistic Rationale | 9 | Strong scientific basis for immune modulation |
| Addresses Root Cause | 8 | Targets immune dysregulation, a core disease mechanism |
| Delivery Feasibility | 6 | Antibodies need CNS penetration; small molecule NLRP3 inhibitors better |
| Safety Plausibility | 7 | CD47 can cause anemia (peripheral target); need brain-selective |
| Combinability | 9 | Can add TREM2 agonists, complement inhibitors |
| Biomarker Availability | 8 | IL-1β, IL-18 in CSF; phagocytic markers emerging[6] |
| De-risking Path | 7 | Components in clinical trials; combo needs optimization |
| Multi-disease Potential | 9 | AD, PD, ALS, MS all have innate immune components |
| Patient Impact | 8 | Could significantly modify disease trajectory |
Total: 79/100
| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| CD47 anemia (peripheral) | High | Moderate | Engineer brain-selective antibodies |
| NLRP3 off-target toxicity | Moderate | High | Use highly selective inhibitors |
| Combination toxicity | Moderate | High | Staggered dosing in Phase 1 |
| Insufficient brain penetration | High | High | Prioritize brain-penetrant scaffolds |
This therapy concept connects to the following established treatment approaches: